The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab
Open accessAbstract
Purpose: To analyze a case series of retinal vasculitis reported to the American Society of Retina Specialists (ASRS) following Food and Drug Administration approval of brolucizumab for treatment of neovascular age-related macular degeneration. Methods: The ASRS Research and Safety in Therapeutics Committee analyzed clinical and imaging characteristics from submitted reports of retinal vasculitis after brolucizumab. Results: Retinal vasculitis was reported in 26 eyes of 25 patients (22 [88%] female) after treatment with brolucizumab. Imaging studies were available for 24 of 26 eyes. Most cases (92%) were associated with intraocular inflammation, which presented at a mean of 25 days (range, 3-63 days) after the most recent brolucizumab injection. Mean visual acuity (VA) was 20/52 (range, 20/25-4/200) before the adverse event, 20/151 (range, 20/25-hand motion) at presentation of the adverse event, and 20/243 (range, 20/30-light perception) at last follow-up. Twelve eyes (46%) had a greater than 3-line decrease in VA at final follow-up, and 12 eyes (46%) had a final VA of 20/200 or worse. Analysis of retinal imaging identified vasculopathy that involved retinal arteries (91%), retinal veins (79%), and choroidal vessels (48%). Occlusive disease was apparent on imaging in 83% of eyes. Treatment approaches were varied. Conclusions: Retinal vasculitis has been identified in a series of eyes following brolucizumab. Although a few eyes in this series were asymptomatic or minimally symptomatic, some eyes had significant vision loss. A careful examination for signs of active inflammation prior to brolucizumab injection is recommended. Once vasculopathy is suspected, angiographic imaging may help define the spectrum of involvement. Optimal treatment strategies remain unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Average time to presentation was 53 days after the last brolucizumab injection (range 8–137 days).”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The largest study outside of the clinical trials to date evaluating retinal vasculitis after brolucizumab is a retrospective analysis of 26 eyes from 25 patients that were reported to the ASRS [37].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The average time to presentation in recent case series has ranged from 30 to 53 days after injection [37, 38].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The female predominance of brolucizumab-associated retinal vasculitis reported by Witkin et al. (22 of 25 patients were female) may point towards an auto-immune response, although no definitive correlation to auto-immune disease has been made [37].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Anterior chamber cell was present in 65% of eyes.”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Occlusive vasculitis was noted in 85% of eyes [37].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Patients had variable extent of retinal vasculitis, with involvement of retinal arteries, veins or choroidal vessels.”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Choroidal ischemia was noted in 10 of 21 eyes.”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“At final follow up, mean final BCVA was 20/243 and 46% had a greater than 3-line decrease in visual acuity.”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical presentation was variable, however 92% of eyes exhibited signs of either anterior inflammation and/or posterior inflammation.”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“This study showed that BCVA worsened from an average baseline of 20/52 to 20/151 at time of presentation.”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Center for Drug Evaluation and Research
National Cancer Institute (2020) · Definitions · doi:10.32388/doq9wu · Cited by 676
Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis
Witkin, A. J., Chang, D. F., Jumper, J. M., Charles, S., Eliott, D., Hoffman, R. S., Mamalis, N., Miller, K. M., & Wykoff, C. C. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.11.042 · Cited by 178
Self-citationRetinal arterial occlusive vasculitis following intravitreal brolucizumab administration
Haug, S. J., Hien, D. L., Uludag, G., Ngoc, T. T. T., Lajevardi, S., Halim, M. S., Sepah, Y. J., Do, D. V., & Khanani, A. M. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100680 · Cited by 142
Georgopoulos, M., Polak, K., Prager, F., Prunte, C., & Schmidt-Erfurth, U. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.138479 · Cited by 124
Jain, A., Chea, S., Matsumiya, W., Halim, M. S., Yaşar, Ç., Kuang, G., Sepah, Y. J., Khanani, A. M., Do, D. V., & Nguyen, Q. D. (2020) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2020.100687 · Cited by 109
Goldberg, R. A., Shah, C. P., Wiegand, T. W., & Heier, J. S. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.06.019 · Cited by 94
Self-citationSacu, S., Pemp, B., Weigert, G., Matt, G., Garhöfer, G., Prünte, C. F., Schmetterer, L. F., & Schmidt-Erfurth, U. M. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5842 · Cited by 85
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Agrawal, S., Joshi, M., & Christoforidis, J. B. (2013) · Mediators of Inflammation · doi:10.1155/2013/943409 · Cited by 83
Postmarketing Analysis of Aflibercept-Related Sterile Intraocular Inflammation
Hahn, P., Chung, M. M., Flynn, H. W., Huang, S. S., Kim, J. E., Mahmoud, T. H., Sadda, S. R., & Dugel, P. U. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.5650 · Cited by 77
Self-citation
Research works printed but not linked: 1
- Haug SJ, 2020, Am J Ophthalmol Case Rep, 100680, 18
Cited by
Sorted by citations
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Wang, L., Liu, W., Broussy, S., Han, B., & Fang, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1307860 · Cited by 169
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Self-citationBaumal, C. R., Bodaghi, B., Singer, M. A., Tanzer, D. J., Seres, A., Joshi, M. R., Feltgen, N., & Gale, R. P. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.09.020 · Cited by 152
Diabetic Retinopathy Preferred Practice Pattern®
Lim, J. I., Kim, S. J., Bailey, S. T., Kovach, J. L., Vemulakonda, G. A., Ying, G., & Flaxel, C. J. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.12.020 · Cited by 133
Self-citation
Metadata
- Authors
- Witkin, A. J., Hahn, P., Murray, T. G., Arevalo, J. F., Blinder, K. J., Choudhry, N., Emerson, G. G., Goldberg, R. A., Kim, S. J., Pearlman, J., Schneider, E. W., Tabandeh, H., & Wong, R. W.
- Affiliations
- Tufts Medical Center, Boston, MA, USA
- NJ Retina, Teaneck, NJ, USA
- Murray Ocular Oncology and Retina, Miami, FL, USA
- Wilmer Eye Institute at Johns Hopkins Hospital, Baltimore, MD, USA
- Retina Institute (US)
- Vitreous Retina Macula Specialists of Toronto, Toronto, ON, Canada
- The Retina Center (US)
- Bay Area Retina Associates (US)
- Vanderbilt University Medical Center (US)
- Retinal Consultants, Sacramento, CA, USA
- Tennessee Retina (US)
- Retina Vitreous Associates Medical Group (US)
- Austin Retina Associates, Austin, TX, USA
- Corresponding author
- Hahn, Paul
- ORCID
- Venue
- Journal of VitreoRetinal Diseases
- Publisher
- SAGE Publications
- Published
- 2020-07
- Volume
- 4
- Issue
- 4
- Pages
- 269-279
- ISSN
- 2474-1264 (ISSN-L)
- 2474-1272
- PMC
- PMC7418897
- OpenAlex
- W3040108021
- Cited by
- 183
- References
- 19
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 27 · 2023: 34 · 2022: 41 · 2021: 46 · 2020: 3
- FWCI
- 24.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of VitreoRetinal Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (EY027691)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Keywords
- brolucizumab, occlusive retinal vasculitis, neovascular age-related macular degeneration, intraocular inflammation, retinal vascular disease, vision loss, anti-VEGF therapy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
